Coloplast’s Q1 18 results came in slightly below expectations, at both the top-line as well as the bottom-line. The strength in the Ostomy and Continence care segments was offset by weakness in wound care. We have tweaked our numbers based on the Q1 results and the Lilial acquisition, but maintain our recommendation on the stock.
14 Mar 2018
Operating profit falls for the first time in over five years
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Operating profit falls for the first time in over five years
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
14 Mar 2018 -
Author:
Jyoti Prakash -
Pages:
3
Coloplast’s Q1 18 results came in slightly below expectations, at both the top-line as well as the bottom-line. The strength in the Ostomy and Continence care segments was offset by weakness in wound care. We have tweaked our numbers based on the Q1 results and the Lilial acquisition, but maintain our recommendation on the stock.